Rifamycin SV MMX®
Hepatic encephalopathy
Phase 2Active
Key Facts
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals is a publicly traded, revenue-generating biopharmaceutical company with a strategic focus on gastroenterology. Its core expertise lies in the MMX® multi-matrix system, a proprietary technology enabling targeted topical delivery of drugs to the colon. The company's strategy combines the commercialization of its approved products, like Uceris® and Methylene Blue MMX®, with the advancement of its clinical pipeline, including novel candidates for ulcerative colitis and Crohn's disease, while also engaging in strategic licensing and partnership agreements.
View full company profileTherapeutic Areas
Other Hepatic encephalopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Xifaxan (rifaximin) | Bausch Health | Approved |